India Lacks Expertise and Tools to Combat Rising Fungal Disease Burden

Every summer for nearly a quarter-century, Sunita's neck breaks out in a dark, burnt-looking rash that spreads across her skin in the heat and humidity of Mumbai. The discoloration persists through the hottest months, a source of quiet shame that sends her reaching for anti-fungal powder and air-conditioned rooms. When the monsoons arrive, the dead skin sheds away as if by magic, and her neck returns to normal—until the next summer comes around. Her doctors have assured her it's nothing serious. But the cycle repeats, year after year, and she remains anxious about the stares and questions it provokes.

Sunita's predicament is far from unique. Across India, an estimated 50 million people contend with fungal infections of varying severity—a burden that ranks among the highest in the world. Yet the country's medical infrastructure, its training systems, and its diagnostic capabilities remain woefully unprepared to address what has become a public health crisis. The World Health Organization flagged fungal pathogens as a priority concern in 2022, noting simultaneously that reliable data on fungal disease prevalence and impact remain scarce. A 2024 analysis in The Lancet Infectious Diseases estimated that 3.8 million people die annually from fungal infections globally, a figure compounded by growing resistance to antifungal medications and deepening uncertainty about whether available drugs will actually work.

India's vulnerability to fungal disease stems partly from geography. Fungi thrive in hot, humid conditions, making tropical nations far more susceptible than temperate ones. But the real problem runs deeper: the country lacks the institutional infrastructure, the trained personnel, and the diagnostic tools that would allow clinicians to identify and treat fungal infections with precision. Unlike tuberculosis or viral diseases, which have spawned dedicated research institutes and specialized training programs, fungal pathogens remain largely orphaned within India's medical establishment. At the L.V. Prasad Eye Institute in Hyderabad, ophthalmologists see three to four cases of fungal eye infection daily—a stark contrast to Western hospitals, where such cases appear perhaps once or twice yearly. During the COVID-19 pandemic, mucormycosis, a black fungus infection, captured public attention and fear. Its prevalence in India runs roughly 80 times higher than in economically developed nations.

The diagnostic challenge is formidable. When a patient presents with symptoms, clinicians typically prescribe antibacterial medications first. Only when those fail do they consider fungal causes—a delay that allows the infection to penetrate deeper into the body and become exponentially harder to treat. Proper fungal identification requires culturing samples on specialized media and examining spore morphology under microscopes, a process that can stretch across weeks. Microbiologists must consult fungal handbooks and databases to distinguish between species based on the color, shape, and size of spores—work that one expert describes as "a dying art." Many Indian microbiology departments do not routinely test for common respiratory fungal infections like aspergillosis, instead continuing to treat negative tuberculosis cases with anti-tuberculosis drugs. The most advanced diagnostic tool available, MALDI-TOF mass spectrometry, can identify fungi in roughly 30 minutes but costs upwards of 1.5 crore rupees for a new unit. Even refurbished machines run to 10 lakh rupees or more. PCR tests, which proved invaluable during the pandemic, are poorly suited to fungi because their tough cell walls require specialized extraction techniques before genetic material can be analyzed.

The knowledge gap extends beyond diagnostics into fundamental biology. Most fungal researchers in India use baker's yeast as a model organism to study eukaryotic cell processes, but those findings rarely translate to clinical relevance. Few scientists focus on filamentous fungi like Aspergillus and Fusarium, which cause many of India's mold infections. Basic questions remain unanswered: what causes a fungus normally found on human skin to suddenly turn pathogenic? How does the fungus interact with its host in its natural state? The shortage of skilled taxonomists who can grow, identify, and maintain fungal cultures compounds the problem. Even among the better-studied Candida infections, understanding remains limited.

Antifungal resistance presents another mounting threat. Fungi exposed repeatedly to antifungal compounds in the environment—through patient self-medication, over-the-counter sales, and agricultural use—develop resistance over time. The pool of available antifungal drugs is already small, constrained by the fact that fungal cells are eukaryotic, like human cells, meaning molecules that kill fungi can also harm patients. Clinicians often lack reliable information about which drugs will actually work against which pathogens, forcing them to make treatment decisions in the dark.

Yet there are signs of movement. Researchers across India are working to identify priority fungal pathogens circulating within the country's borders, mapping antifungal resistance in environmental samples, and developing new therapeutics such as antimicrobial peptides. Better-equipped hospitals are beginning to train colleagues in recognizing fungal infections as an urgent crisis. The challenge now is whether these efforts can scale quickly enough to meet a burden that affects tens of millions and continues to grow.